Encorafenib (Braftovi) is a kinase inhibitor that was first approved in the United States in 2018 for the treatment of advanced malignant tumors harboring specific BRAF gene mutations.

How to Use Encorafenib (Braftovi)

For Melanoma

Indicated for unresectable or metastatic melanoma with BRAF V600E or V600K mutation.

The recommended dosage is 450 mg (6 capsules of 75 mg each) taken once daily, in combination with binimetinib.

For Colorectal Cancer

When used in combination with cetuximab and mFOLFOX6, the recommended dosage is 300 mg (4 capsules of 75 mg each) taken once daily.

When used in combination with cetuximab alone, the recommended dosage is 300 mg taken once daily.

For Non-Small Cell Lung Cancer (NSCLC)

Indicated for metastatic non-small cell lung cancer with BRAF V600E mutation.

The recommended dosage is 450 mg taken once daily, in combination with binimetinib.

Precautions for Administration

The BRAF mutation status must be confirmed using a detection method approved by the FDA before initiating medication.

The drug can be taken with or without food; it is recommended to administer it at a fixed time every day.

If a dose is missed, take the missed dose as soon as you remember. However, if it is less than 12 hours before the next scheduled dose, skip the missed dose.

If vomiting occurs after taking the drug, do not take an additional dose to make up for it.

Dosage Adjustment of Encorafenib (Braftovi)

For Patients with Melanoma or Non-Small Cell Lung Cancer

First dose reduction: Decrease from 450 mg to 300 mg.

Second dose reduction: Decrease from 300 mg to 225 mg.

If the 225 mg dose is not tolerated, permanent discontinuation of the drug is required.

For Patients with Colorectal Cancer

First dose reduction: Decrease from 300 mg to 225 mg.

Second dose reduction: Decrease from 225 mg to 150 mg.

If the 150 mg dose is not tolerated, permanent discontinuation of the drug is required.

For Cardiotoxicity

If symptomatic heart failure occurs, or left ventricular ejection fraction (LVEF) decreases by >20% from baseline and falls below the lower limit of normal: Reduce the dose by one level.

If LVEF improves to the normal range and the decrease from baseline is ≤10%: Continue treatment with the reduced dose.

Medication for Special Populations of Encorafenib (Braftovi)

Patients with Hepatic or Renal Impairment

Mild hepatic impairment (Child-Pugh Class A): No dosage adjustment is required.

Moderate to severe hepatic impairment (Child-Pugh Class B/C): The recommended dosage has not been determined.

Mild to moderate renal impairment: No dosage adjustment is required.

Severe renal impairment: The recommended dosage has not been determined.

Women of Childbearing Age and Pregnant Patients

Pregnancy: The drug has embryo-fetal toxicity and may cause fetal harm.

Women of childbearing age: Effective non-hormonal contraceptive methods must be used during treatment and for 2 weeks after the last dose.

Lactating Patients

It is recommended to discontinue breastfeeding during treatment and for 2 weeks after the last dose.